东北制药公告，2025年上半年营业收入38.53亿元，同比下降7.58%。净利润1.29亿元，同比下降 17.62%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

证券日报网讯东北制药（000597）8月26日在互动平台回答投资者提问时表示，截至2025年8月20日，持 有人数约5.11万户。 ...

Core Insights - The article highlights the strategic focus of Northeast Pharmaceutical, a subsidiary of Fangda Group, on attracting high-level talent to drive innovation and development in the pharmaceutical industry [2][4]. Group 1: Talent Strategy - Fangda Group emphasizes the importance of recruiting high-end talent to ensure sustainable development over the next 10 to 30 years, aligning talent acquisition with the company's overall development strategy [2]. - Northeast Pharmaceutical plans to recruit 300 master's and doctoral graduates annually for three consecutive years, focusing on drug research and development, chemical drug transformation, cell therapy technology breakthroughs, and modernization of traditional Chinese medicine [2][4]. Group 2: Talent Attraction - The company has established a comprehensive research and development system covering chemical drugs, biological drugs, and traditional Chinese medicine, enhancing its appeal to new talent [3]. - Recruitment efforts included engaging with 28 universities and participating in 35 job fairs, resulting in the selection of 100 master's and doctoral graduates from over 1,600 applications [3]. Group 3: Employee Welfare - Northeast Pharmaceutical offers competitive salaries and unique benefits such as medical expense assistance, mobile phone allowances, and family-oriented programs, fostering a supportive environment for employees and their families [5]. - The company has created a comprehensive talent management system that includes recruitment, training, and retention strategies, ensuring a positive cycle of talent engagement and contribution to the company [5].

Group 1 - The company Northeast Pharmaceutical disclosed that as of July 31, the number of shareholders was 46,700, which represents a decrease of 3,600 shareholders compared to the previous period (July 20), resulting in a month-on-month decline of 7.16% [2]

8月4日，东北制药连续6个交易日下跌，区间累计跌幅-5.55%。东北制药集团股份有限公司,是辽宁方大集团实业有限公司旗下上市公司。 财报显示，南方基金旗下南方中证1000ETF为东北制药前十大股东，今年一季度减持。今年以来收益率14.26%，同类排名765(总2930)。 | 阶段涨幅 | 李度涨幅 年度涨幅 | | | | | | --- | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 近6月 | 今年来 | | 阶段涨幅 | 0.15% | 6.92% | 14.29% | 16.39% | 14.26% | | 同类平均6 | -1.36% | 4.61% | 10.88% | 12.33% | 10.14% | | 沪深300 | -1.57% | 2.22% | 7.96% | 6.64% | 3.45% | | 跟踪标的� | 0.14% | 6.77% | 13.27% | 15.29% | 13.13% | | 同类排名 3 | 665 3449 | 953 3423 " | 832 3252 | 716 2997 | 765 293 ...

Core Insights - The cell immunotherapy sector saw a 2.42% increase, ranking 6th among concept sectors, with 42 stocks rising, led by Ruizhi Pharmaceutical with a 20% limit-up [1] - Major inflows were observed in the cell immunotherapy sector, with a net outflow of 239 million yuan, while 31 stocks experienced net inflows, with Ruizhi Pharmaceutical leading at 235 million yuan [1][2] Group 1: Sector Performance - The cell immunotherapy concept had a 2.42% increase, with notable performers including Ruizhi Pharmaceutical (20.02%), Sanyuan Gene (20.76%), and Haitai Biological (15.28%) [1] - The sector's performance was contrasted by declines in stocks like Saili Medical (-4.62%), Zexin Pharmaceutical (-3.47%), and Xue Rong Biological (-2.39%) [1] Group 2: Fund Flow Analysis - Ruizhi Pharmaceutical, Jinyu Medical, and Chengda Pharmaceutical had the highest net inflow ratios at 15.31%, 10.34%, and 9.67% respectively [2] - The top stocks by net inflow included Ruizhi Pharmaceutical (234.82 million yuan), Hanyu Pharmaceutical (73.39 million yuan), and Jiu Zhitang (49.52 million yuan) [2][3] Group 3: Stock Performance - Stocks like Haitai Biological and Yuedong Pharmaceutical showed significant gains, with Haitai Biological rising by 15.28% and Yuedong Pharmaceutical by 9.96% [1][4] - Conversely, stocks such as Saili Medical and Zexin Pharmaceutical faced notable declines, with Saili Medical down by 4.62% and Zexin Pharmaceutical by 3.47% [5]

证券代码：000597 证券简称：东北制药 公告编号：2025-056 东北制药集团股份有限公司 关于聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）于2025年7月28日召开第十届 董事会第四次会议，审议通过了《关于聘任董事会秘书的议案》。具体情况如下： 传真：024-25806400 经公司董事长周凯先生提名，公司董事会提名委员会审核，公司董事会同意聘 任宋立志先生为董事会秘书（简历详见附件），任期自本次董事会审议通过之日起 至第十届董事会届满之日止。同时，公司董事长周凯先生不再代行董事会秘书职责。 宋立志先生已取得深圳证券交易所颁发的《董事会秘书资格证书》，熟悉董事 会秘书履职相关的法律法规，具备与岗位相应的专业能力，符合《中华人民共和国 公司法》《深圳证券交易所股票上市规则》等法律法规及《公司章程》的规定。 联系电话：024-25806963 电子邮箱：dshbgs@nepharm.com.cn 联系地址：沈阳经济技术开发区昆明湖街8号 宋立志先生的联系方式如下： 1 附件： 董事会秘书 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-055 第十届董事会第四次会议决议公告 东北制药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 1.东北制药集团股份有限公司（以下简称"公司"）第十届董事会第四次会 议于 2025 年 7 月 21 日发出会议通知，于 2025 年 7 月 28 日以通讯表决的方式召 开。 2.会议应参加董事 11 人，实际参加董事 11 人。 3.本次会议的召集、召开和表决程序符合有关法律、行政法规、部门规章、 规范性文件和《东北制药集团股份有限公司章程》的规定，会议形成的决议合法 有效。 二、董事会会议审议情况 会议审议并以记名投票表决方式通过以下议案： 议案：关于聘任董事会秘书的议案 具体内容详见公司于同日披露于巨潮资讯网的《东北制药集团股份有限公司 关于聘任董事会秘书的公告》（公告编号：2025-056） 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案在提交董事会审议前，已通过董事会提名委员会审核。 三、备查文件 东北制药集团股份有限公司第十届董事 ...

Core Viewpoint - Northeast Pharmaceutical has significantly improved its operational quality and company value since its mixed-ownership reform in 2018, driven by market-oriented strategies and innovation in the pharmaceutical industry [1][2]. Group 1: Mixed-Ownership Reform - The introduction of Liaoning Fangda Group as a strategic investor in 2018 has led to a clearer market position and a more scientific corporate governance structure, effectively addressing the issues of market-oriented operation [2]. - The company has increased its R&D investment and adopted a three-pronged approach to its R&D strategy, focusing on independent development, joint development, and project introduction [2][3]. - Northeast Pharmaceutical has established a biological research base in Shanghai and successfully acquired Dingcheng Peptide Source, enhancing its capabilities in cancer cell therapy [2]. Group 2: Talent and Management Innovation - The company has initiated a large-scale recruitment of master's and doctoral talents to strengthen its research capabilities, aiming to create a competitive edge in the biopharmaceutical sector [3]. - A new management model has been implemented, allowing for efficient communication of employee suggestions to decision-makers, resulting in numerous improvements and economic benefits [3][4]. - The company has established a robust incentive mechanism, rewarding employees for cost-saving and innovative suggestions, which has fostered a culture of engagement and productivity [3][4]. Group 3: Quality Control and Production Efficiency - Northeast Pharmaceutical has maintained a strong commitment to product quality, successfully passing a rigorous FDA inspection with zero defects, which enhances its reputation in international markets [5]. - The company has implemented advanced information technology to innovate its production processes and management models, improving efficiency and product quality [6]. - The focus on quality control and the introduction of smart production lines have led to higher production efficiency and lower costs, increasing the competitiveness of the company's products [6].

Core Viewpoint - The company, Northeast Pharmaceutical Group Co., Ltd., has received notification from its controlling shareholder, Liaoning Fangda Group Industrial Co., Ltd., regarding the pledge of a portion of its shares [2]. Summary by Relevant Sections Share Pledge Details - Liaoning Fangda Group pledged 48,740,000 shares, which accounts for 14.81% of its total holdings and 3.42% of the company's total share capital [2]. - The pledge is not part of a controlling shareholder's actions and does not affect the company's overall shareholding structure [2]. Cumulative Pledge Situation - Before this pledge, the total number of shares pledged by Liaoning Fangda Group was 329,068,713, representing 23.06% of its holdings [5]. - After the current pledge, the total pledged shares will increase to 285,062,211, which is 42.42% of the total shares held by the group [5]. - The company will continue to monitor the share pledge situation and will disclose relevant information in accordance with regulations [5].